Evidence map›Paper›PMID 31465488›Full record

ArticlePloS one2019

Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects.

Paweł Wiczling, Emilia Daghir-Wojtkowiak, Roman Kaliszan, Michał Jan Markuszewski, Janusz Limon, Magdalena Koczkowska, Maciej Stukan, Alina Kuźniacka, Magdalena Ratajska

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. The Role of miRNA in Ovarian Cancer: an Overview.Reproductive sciences (Thousand Oaks, Calif.) · 2022
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paweł WiczlingDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gen. J. Hallera, Gdańsk, Poland.ORCID 0000-0002-2878-3161
Emilia Daghir-WojtkowiakDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gen. J. Hallera, Gdańsk, Poland.
Roman KaliszanDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gen. J. Hallera, Gdańsk, Poland.
Michał Jan MarkuszewskiDepartment of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gen. J. Hallera, Gdańsk, Poland.ORCID 0000-0003-1166-4817
Janusz LimonDepartment of Biology and Genetics, Medical University of Gdańsk, Dębinki, Gdańsk, Poland.
Magdalena KoczkowskaDepartment of Biology and Genetics, Medical University of Gdańsk, Dębinki, Gdańsk, Poland.
Maciej StukanDepartment of Gynecological Oncology, Gdynia Oncology Centre, Powstania Styczniowego, Gdynia, Poland.
Alina KuźniackaDepartment of Biology and Genetics, Medical University of Gdańsk, Dębinki, Gdańsk, Poland.ORCID 0000-0002-9396-3273
Magdalena RatajskaDepartment of Biology and Genetics, Medical University of Gdańsk, Dębinki, Gdańsk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In transcriptomics, micro RNAs (miRNAs) has gained much interest especially as potential disease indicators. However, apart from holding a great promise related to their clinical application, a lot of inconsistent results have been published. Our aim was to compare the miRNA expression levels in ovarian cancer and healthy subjects using the Bayesian multilevel model and to assess their potential usefulness in diagnosis. We have analyzed a case-control observational data on expression profiling of 49 preselected miRNA-based ovarian cancer indicators in 119 controls and 59 patients. A Bayesian multilevel model was used to characterize the effect of disease on miRNA levels controlling for differences in age and body weight. The difference between the miRNA level and health status of the patient on the scale of the data variability were discussed in the context of their potential usefulness in diagnosis. Additionally, the cross-validated area under the ROC curve (AUC) was used to assess the expected out-of-sample discrimination index of a different sets of miRNAs. The proposed model allowed us to describe the set of miRNA levels in patients and controls. Three highly correlated miRNAs: miR-101-3p, miR-142-5p, miR-148a-3p rank the highest with almost identical effect sizes that ranges from 0.45 to 1.0. For those miRNAs the credible interval for AUC ranged from 0.63 to 0.67 indicating their limited discrimination potential. A little benefit in adding information from other miRNAs was observed. There were several miRNAs in the dataset (miR-604, hsa-miR-221-5p) for which inferences were uncertain. For those miRNAs more experimental effort is needed to fully assess their effect in the context of new hits discovery and usefulness as disease indicators. The proposed multilevel Bayesian model can be used to characterize the panel of miRNA profile and to assess the difference in expression levels between healthy and cancer individuals.

Indexed as

Multilevel AnalysisBayes TheoremCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedModels, BiologicalOvarian NeoplasmsMicroRNAs

Identifiers

PMID31465488
PMCPMC6715278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.